Trials / Completed
CompletedNCT02517320
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 293 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first morning void urine sample as an indicator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-3995 Low | |
| DRUG | MT-3995 Middle | |
| DRUG | MT-3995 High | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-11-01
- Completion
- 2017-01-01
- First posted
- 2015-08-07
- Last updated
- 2017-03-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02517320. Inclusion in this directory is not an endorsement.